Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting

Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting

BackgroundPriming with two doses of AZD1222 (Oxford-AstraZeneca; ChAd) followed by a third mRNA vaccine boosting is considered in several countries, yet comparisons between heterologous and homologous booster efficacy remain unexplored. AimTo evaluate and contrast the immunogenicity of homologous an...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Salma, Younes (author)
مؤلفون آخرون: Nicolai, Eleonora (author), Younes, Nadin (author), Pieri, Massimo (author), Bernardini, Sergio (author), Nizamuddin, Parveen B. (author), Al-Sadeq, Duaa W. (author), Daas, Hanin I. (author), Ismail, Ahmed (author), Yassine, Hadi M. (author), Abu-Raddad, Laith J. (author), Nasrallah, Gheyath K. (author)
التنسيق: article
منشور في: 2024
الموضوعات:
AZD1222 (Oxford-AstraZeneca, ChAd)
Homologous
Heterologous
mRNA vaccination
Neutralizing antibody
Anti-S1 IgA
الوصول للمادة أونلاين:http://dx.doi.org/10.1016/j.vaccine.2024.06.010
https://www.sciencedirect.com/science/article/pii/S0264410X24006698
http://hdl.handle.net/10576/58683
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

الانترنت

http://dx.doi.org/10.1016/j.vaccine.2024.06.010
https://www.sciencedirect.com/science/article/pii/S0264410X24006698
http://hdl.handle.net/10576/58683

مواد مشابهة